Disease Diagnosis TRIZ Cases
- msiCAT-Tailing Biomarkers for Detecting and Targeting Cancer Stem Cells
Detecting msiCAT-tailing proteins reveals cancer stem cells and drug resistance, guiding inhibitor-based treatment to restore susceptibility.
- Peanut Allergen Release Profiling by Digestion and Mass Spectrometry
Digestion and LC-MS-MS profiling detects low-level peanut allergen signatures and release profiles for batch consistency and in vivo prediction.
- FGFBP1 Blood Biomarker Detection for Earlier PCOS Diagnosis
Measuring FGFBP1 in blood simplifies inconsistent PCOS diagnosis and supports earlier assessment, monitoring, and treatment selection.
- IGFBP7-to-BNP Ratio for Differentiating HFpEF and HFrEF
Using IGFBP7-to-BNP and IGFBP7+CRP-to-BNP ratios improves differentiation between HFpEF and HFrEF when single biomarkers lack accuracy.
- Structure-Specific Peptide Probes for Early Preeclampsia Detection
Selective peptide probes detect transthyretin aggregates to support earlier preeclampsia diagnosis and therapeutic monitoring.
- LARP1 EGYR Peptide Quantification for Reliable Cancer Monitoring
Trypsin-released EGYR peptide measured by chromatography-tandem mass spectrometry improves reliable LARP1 quantification in blood samples.
- Food Sensitivity Test Kit Using Gender-Stratified IgG Cutoffs
Statistically selected food preparations and gender-specific IgG cutoffs improve functional dyspepsia trigger-food testing accuracy.
- Alpha-Synuclein PMCA Detection for Early Parkinson's Diagnosis
Cyclic amplification with monomeric alpha-synuclein and aggregate disruption enables ultra-sensitive detection of misfolded protein for earlier Parkinson's diagnosis.
- ME-Score Prediction of Immunotherapy Response in mCRC Metastases
An ME-score based on CD8+ T cells, dendritic cells, and macrophages predicts which mCRC metastases may respond to immunotherapy.
- Protein Biomarker Panel for Early AKI Risk Stratification
Multiple protein markers plus clinical variables improve acute kidney injury risk prediction before procedures, enabling earlier intervention.
- Alpha-Synuclein PMCA Fluorescence for PD-MSA Diagnosis
Fluorescence-based PMCA amplifies misfolded alpha-synuclein from biological samples to distinguish Parkinson's disease from MSA with higher specificity.